{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:37:05Z","timestamp":1792183025439,"version":"4.4.0"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["14427084"],"award-info":[{"award-number":["14427084"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate oral prosultiamine treatment in patients with overactive bladder accompanied by human T\u2010lymphotropic virus type 1\u2010associated myelopathy\/tropical spastic paraparesis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a prospective, single\u2010center, open\u2010label study. Patients received oral prosultiamine (300 mg) once daily in the morning, and the overactive bladder symptom score and urine levels of overactive bladder\u2010related biomarkers (nerve growth factor\/creatinine and adenosine triphosphate\/creatinine) 12 weeks after the initial administration were compared with the baseline values. In addition, the urodynamic parameters, including involuntary detrusor contraction and detrusor sphincter dyssynergia, were evaluated before and after treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 16 patients were recruited for this clinical study. In the overactive bladder symptom score, night\u2010time frequency, urgency and the total score improved after oral prosultiamine treatment (<jats:italic>P<\/jats:italic> = 0.028, 0.001 and 0.004, respectively). Both urinary nerve growth factor\/creatinine and adenosine triphosphate\/creatinine levels decreased significantly after the treatment (<jats:italic>P<\/jats:italic> = 0.004 and 0.017, respectively). Urodynamic studies showed that the maximum cystometric capacity increased significantly after the treatment. However, the symptoms disappeared because of the treatment in six of 10 patients with involuntary detrusor contraction (60%) and three of seven patients with detrusor sphincter dyssynergia (42.9%). There were no serious adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The changes in urodynamic parameters and urine levels of overactive bladder\u2010related markers suggest that oral prosultiamine is a safe and effective treatment for overactive bladder with human T\u2010lymphotropic virus type 1\u2010associated myelopathy\/tropical spastic paraparesis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.13468","type":"journal-article","created":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T23:42:44Z","timestamp":1506901364000},"page":"54-60","source":"Crossref","is-referenced-by-count":8,"title":["Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T\u2010lymphotropic virus type 1\u2010associated myelopathy\/tropical spastic paraparesis"],"prefix":"10.1111","volume":"25","author":[{"given":"Tomohiro","family":"Matsuo","sequence":"first","affiliation":[{"name":"Department of Urology Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Miyata","sequence":"additional","affiliation":[{"name":"Department of Urology Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsufumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Social Work Faculty of Human and Social Studies Nagasaki International University Sasebo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Satoh","sequence":"additional","affiliation":[{"name":"Unit of Rehabilitation Sciences Department of Locomotive Rehabilitation Science Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Urology Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.12.7415"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)91298-5"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-182"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.01.052"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1807-59322007000200015"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-55382007000200016"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0029-2014"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2008.01.004"},{"key":"e_1_2_8_10_1","first-page":"251","article-title":"Clinical efficacy of an anticholinergic agent in HAM\/TSP patients with neurogenic bladder","volume":"3","author":"Castro NM","year":"2005","journal-title":"Einstein"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a126421"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2183\/pjab1945.28.146","article-title":"On the structure of allithiamine","volume":"28","author":"Matsukawa T","year":"1952","journal-title":"Proc. Jpn. Acad."},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/135965350901400412","article-title":"Disulfide\u2010mediated apoptosis of human T\u2010lymphotropic virus type\u20101 (HTLV\u20101)\u2010infected cells in patients with HTLV\u20101\u2010associated myelopathy\/tropical spastic paraparesis","volume":"14","author":"Nishiura Y","year":"2009","journal-title":"Antivir. Ther."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08380.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-013-2104-0"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-015-2825-3"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22939"},{"key":"e_1_2_8_18_1","first-page":"207","article-title":"Renoprotective effects of telmisartan after unilateral renal ablation in rats","volume":"6","author":"Matsuo T","year":"2013","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10066"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02774.x"},{"key":"e_1_2_8_23_1","article-title":"Prevalence of Sj\u00f6gren's syndrome in Brazilian patients infected with human T\u2010cell lymphotropic virus","author":"Vale DA","year":"2016","journal-title":"J. Oral Pathol. Med."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.03.080"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(90)90060-Z"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.1992.tb00132.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00692.x"},{"key":"e_1_2_8_28_1","first-page":"254","article-title":"Polyclonal use of T\u2010cell receptor a for human T\u2010cell lymphotropic virus type 1\u2010infected T cells","volume":"36","author":"Masuoka K","year":"1995","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.13468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.13468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T21:32:59Z","timestamp":1695936779000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.13468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/iju.13468"],"URL":"https:\/\/doi.org\/10.1111\/iju.13468","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}